Ware Kuschner, MD
Critical Care Medicine · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Kuschner’s office at (650) 493-5000 to ask if they take your plan before you enroll.
Money from drug and device companies
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Genentech, Inc. · Ph III Study To Evaluate the Efficacy and Safety of Astegolimab in Copd · 2024 | Their institution | $28,975 |
| SANOFI US SERVICES INC. · Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 3 Study To Evaluate the Efficacy, Safety, and Tolerability of Sar440340/Regn3500/Itepekimab (Anti-Il-33 Mab) in Patients With Moderate-To-Severe Chronic Obstructive Pulmonary Disease (Copd) · 2022 | Their institution | $5,600 |
| Genentech, Inc. · Ph III Study To Evaluate the Efficacy and Safety of Astegolimab in Copd · 2025 | Their institution | $5,000 |
Professional record
- NPI
- 1700805389
- Licence
- CA G074355
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RC0200X (207RC0200X); Federal specialty code 207RP1001X (207RP1001X)
- Mailing address
- 3801 Miranda Avenue, Mail Stop 111p, Palo Alto, CA, 94304
- NPI first listed
- 2006-07-18
- NPI last updated
- 2025-09-11
This is when the NPI record was last certified, not a medical board exam.